Novo goes early to leapfrog haemophilia gene therapies
Novo Nordisk took an early step towards genome editing with yesterday’s Bluebird tie-up, and isn’t ruling out a move into conventional gene therapies.
Novo makes another early-stage diabetes bet with Ziylo buy
The Danish company’s latest deal covers glucose-sensitive insulin, which could avoid hypoglycaemia in type 2 diabetes patients.
How machines could mine forgotten data
Drug discovery is getting harder, and some companies are turning to machine learning to look for new targets.
Storm hopes to rain on Accent’s parade
Epigenetics has so far failed to live up to the hype. But one UK player, Storm Therapeutics, still hopes to make a mark in a new field, RNA therapeutics.
Why Immatics could soon become the next listed cell therapy player
Immunocore and Adaptimmune could shortly have a publicly listed rival.
Takeda forges another neuroscience deal as Abbvie dips a toe
Takeda's appetite for risk in early stage neuroscience could make it one to watch.
